FDA Approves Dayvigo/Lemborexant for Insomnia
The US FDA has approved the orexin receptor antagonist Dayvigo (lemborexant) for the treatment of insomnia, according to manufacturer Eisai Co Ltd.
The US FDA has approved the orexin receptor antagonist Dayvigo (lemborexant) for the treatment of insomnia, according to manufacturer Eisai Co Ltd.
Biologists have identified a gene, neuromedin U (Nmu), that when over activated causes severe insomnia.
A number of recent studies show a link between sleep apnea and congestive heart failure